By IDSE News Staff
After 240 weeks, fostemsavir (Rukobia, ViiV Healthcare) helped heavily treatment-experienced (HTE) adults with multidrug-resistant (MDR) HIV-1 infection achieve durable virologic responses, according to data presented at AIDS 2022, in Montreal.
The BRIGHTE study is an international, two-cohort (randomized and non-randomized), phase 3 clinical trial evaluating the safety and efficacy of fostemsavir, a first-in-class attachment inhibitor, used with optimized background treatment